FDA clears restricted return of multiple sclerosis drug to market Reno Gazette-Journal Tue, 06 Jun 2006 1:40 AM PDT WASHINGTON -- A multiple sclerosis drug pulled from the market last year because of a rare but life-threatening side effect will return under a restricted distribution program, health officials said Monday. Tysabri FDA Approval Under Special Distribution Program For Multiple Sclerosis Medical News Today Mon, 05 Jun 2006 1:10 PM PDT The FDA has approved the resumption of Tysabri (natalizumab), a drug for patients with a relapsing form of multiple sclerosis, under a special restricted distribution program. Tysabri, a monoclonal antibody, helps reduce the number of flare-ups for MS patients. Tysabri is used for patients who have not responded well to other MS treatments. [click link for full article] FDA allows MS drug Tysabri back on market Reuters via Yahoo! News Mon, 05 Jun 2006 2:37 PM PDT U.S. health officials cleared the way on Monday for multiple sclerosis drug Tysabri to return to the market with restrictions, following its withdrawal last year when it was linked to a rare but potentially fatal brain disease. FDA clears restricted return of MS drug to market in United States CP via Yahoo! Canada News Tue, 06 Jun 2006 7:48 AM PDT WASHINGTON (AP) - A multiple sclerosis drug pulled from the market last year because of a rare but life-threatening side-effect will return under a restricted distribution program, U.S. health officials said Monday. FDA Allows Return of MS Drug HealthDay via Yahoo! News Mon, 05 Jun 2006 2:02 PM PDT MONDAY, June 5 (HealthDay News) -- Setting strict guidelines as a condition, the U.S. Food and Drug Administration said Monday that it will allow the reintroduction of the multiple sclerosis drug Tysabri. US OKs resumed sales of Biogen and Elan's Tysabri Reuters via Yahoo! News Mon, 05 Jun 2006 11:03 AM PDT Biogen Idec Inc. and Elan Corp. won permission on Monday to resume sales of their multiple sclerosis drug Tysabri, which was withdrawn last year after it was linked to a rare but potentially fatal brain disease, U.S. regulators said. SCIENCE DIGEST: MS drug gets 2nd chance, with limitations The Charlotte Observer Tue, 06 Jun 2006 3:09 AM PDT A multiple sclerosis drug pulled from the market last year because of a rare but life-threatening side effect will return under a restricted distribution program, health officials said Monday. The Food and Drug Administration said it will let Biogen Idec Inc. and Elan Corp. PLC resume selling Tysabri under a requirement that doctors, pharmacies and patients register with a program designed to MS drug to return with new warning Philly.com Tue, 06 Jun 2006 0:04 AM PDT A multiple sclerosis drug pulled from the market last year because of a rare but life-threatening side effect will return under a restricted distribution program, health officials said yesterday. FDA Allows Return of MS Drug HealthCentral.com Mon, 05 Jun 2006 11:18 PM PDT MONDAY, June 5 (HealthDay News) -- Setting strict guidelines as a condition, the U.S. Food and Drug Administration said Monday that it will allow the return of the multiple sclerosis drug Tysabri. MS sufferers relieved as drug Tysabri goes back on the market News-Medical-Net Tue, 06 Jun 2006 4:10 AM PDT The Food and Drug Administration in the U.S. has given it's approval for the multiple sclerosis drug Tysabri to be put back on the market.